A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 3, 2011, Pages 768-778

  Ni, Nathan C ^a   Yan, Dong ^a   Ballantyne, Laurel L ^a   Barajas Espinosa, Alma ^a   St Amand, Tim ^a   Pratt, Derek A ^b   Funk, Colin D ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[(3 CARBOXYCYCLOHEXYL)AMINO]CARBONYL] 4 [3 [4 (4 PHENOXYBUTOXY)PHENYL]PROPOXY]BENZOIC ACID; 6 (4 CARBOXYPHENYLTHIO) 5 HYDROXY 7,9,11,14 ICOSATETRAENOIC ACID; CYSTEINYLLEUKOTRIENE RECEPTOR 1; CYSTEINYLLEUKOTRIENE RECEPTOR 2; EVANS BLUE; LEUKOCYTE ADHESION MOLECULE; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LYMPHOCYTE ANTIGEN; PEPTIDOLEUKOTRIENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CALCIUM MOBILIZATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; GENE EXPRESSION; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; IC 50; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OTORRHEA; PRIORITY JOURNAL; REPERFUSION INJURY;

ANIMALS; ARRESTINS; BETA-GALACTOSIDASE; CAPILLARY PERMEABILITY; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EAR; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE D4; MICE; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; PEROXIDASE; PHTHALIC ACIDS; RECEPTORS, LEUKOTRIENE; SRS-A;

EID: 80054082807     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.186031     Document Type: Article

References (35)

1. Barajas-Espinosa A, Ochoa-Cortes F, Moos MP, Daniel Ramirez F, Vanner SJ, and Funk CD (2011) Characterization of the cysteinyl leukotriene 2 receptor in novel expression sites of the gastrointestinal tract. Am J Pathol 178:2682-2689.
2. Carnini C, Accomazzo MR, Borroni E, Vitellaro-Zuccarello L, Durand T, Folco G, Rovati GE, Capra V, and Sala A (2011) Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor. FASEB J 25:3519-3528.
3. Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, Ferrario S, Parravicini C, Capra V, Gelosa P, et al. (2006) The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 25:4615-4627. (Pubitemid 44498134)
4. Coutts IGC, Edwards M, and Richards DJ (1981) Mild selective hydrolysis of the methyl esters of some ortho-substituted aromatic carboxylic acids. Synthesis 1981:487-489.
5. Di Gennaro A, Wågsäter D, Mäyränpää MI, Gabrielsen A, Swedenborg J, Hamsten A, Samuelsson B, Eriksson P, and Haeggström JZ (2010) Increased expression of leukotriene C4 synthase and predominant formation of cysteinyl-leukotrienes in human abdominal aortic aneurysm. Proc Natl Acad Sci U S A 107:21093-21097.
6. Funk CD (2005) Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 4:664-672.
7. Haerter M, Ergueden J, Wunder F, Tinel H, Koebberling J, Becker E, Muenter K, Schlemmer K, Kast R, Kolkhof P, et al. (2009) inventors; Bayer Healthcare AG, assignee. Isophthalic acid derivatives. U.S. patent 7,498,460. 2009 March 3.
8. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, Cheng R, et al. (2000) Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275:30531-30536.
9. Helgadottir A, Manolescu A, Helgason A, Thorleifsson G, Thorsteinsdottir U, Gudbjartsson DF, Gretarsdottir S, Magnusson KP, Gudmundsson G, Hicks A, et al. (2006) A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 38:68-74. (Pubitemid 43011884)
10. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, Samani NJ, Gudmundsson G, Grant SF, Thorgeirsson G, et al. (2004) The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36:233-239. (Pubitemid 38282747)
11. Hui Y, Cheng Y, Smalera I, Jian W, Goldhahn L, Fitzgerald GA, and Funk CD (2004) Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 110:3360-3366. (Pubitemid 39557500)
12. Jiang W, Hall SR, Moos MP, Cao RY, Ishii S, Ogunyankin KO, Melo LG, and Funk CD (2008) Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury. Am J Pathol 172:592-602. (Pubitemid 351354533)
13. Kamohara M, Takasaki J, Matsumoto M, Matsumoto Si, Saito T, Soga T, Matsushime H, and Furuichi K (2001) Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells. Biochem Biophys Res Commun 287:1088-1092. (Pubitemid 32980563)
14. Lewin AH, Szewczyk J, Wilson JW, and Carroll FI (2005) Galanthamine analogs: 6H-benzofuro[3a,3,2,-e,f][1]benzazepine and 6H-benzofuro[3a,3,2-e,f][3] benzazepine. Tetrahedron 61:7144-7152. (Pubitemid 40840623)
15. Lötzer K, Spanbroek R, Hildner M, Urbach A, Heller R, Bretschneider E, Galczenski H, Evans JF, and Habenicht AJ (2003) Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 23:e32-e36.
16. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, et al. (1999) Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399:789-793. (Pubitemid 29293175)
17. Maekawa A, Balestrieri B, Austen KF, and Kanaoka Y (2009) GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4. Proc Natl Acad Sci U S A 106:11685-11690.
18. Maekawa A, Kanaoka Y, Xing W, and Austen KF (2008) Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A 105:16695-16700.
19. Moos MP and Funk CD (2008) Endothelial cysteinyl leukotriene 2 receptor expression and myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 18:268-273.
20. Moos MP, Mewburn JD, Kan FW, Ishii S, Abe M, Sakimura K, Noguchi K, Shimizu T, and Funk CD (2008) Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport. FASEB J 22:4352-4362.
21. Nonaka Y, Hiramoto T, and Fujita N (2005) Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun 337:281-288. (Pubitemid 41393791)
22. Qi LL, Fang SH, Shi WZ, Huang XQ, Zhang XY, Lu YB, Zhang WP, and Wei EQ (2011) CysLT2 receptor-mediated AQP4 up-regulation is involved in ischemic-like injury through activation of ERK and p38 MAPK in rat astrocytes. Life Sci 88:50-56.
23. Qiu H, Gabrielsen A, Agardh HE, Wan M, Wetterholm A, Wong CH, Hedin U, Swedenborg J, Hansson GK, Samuelsson B, et al. (2006) Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci U S A 103:8161-8166. (Pubitemid 43801069)
24. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, Moos MP, Kaiser B, Cohnert TU, Wahlers T, et al. (2003) Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A 100:1238-1243. (Pubitemid 36183986)
25. Takase B, Kurita A, Maruyama T, Uehata A, Nishioka T, Mizuno K, Nakamura H, Katsura K, and Kanda Y (1996) Change of plasma leukotriene C4 during myocardial ischemia in humans. Clin Cardiol 19:198-204. (Pubitemid 26314330)
26. Thompson C, Cloutier A, Bossé Y, Poisson C, Larivée P, McDonald PP, Stankova J, and Rola-Pleszczynski M (2008) Signaling by the cysteinyl-leukotriene receptor 2. Involvement in chemokine gene transcription. J Biol Chem 283:1974-1984.
27. Uzonyi B, Lötzer K, Jahn S, Kramer C, Hildner M, Bretschneider E, Radke D, Beer M, Vollandt R, Evans JF, et al. (2006) Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. Proc Natl Acad Sci U S A 103:6326-6331.
28. Vinten-Johansen J (2004) Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 61:481-497.
29. Wunder F, Tinel H, Kast R, Geerts A, Becker EM, Kolkhof P, Hütter J, Ergüden J, and Härter M (2010) Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol 160:399-409.
30. Xu L, Zhang L, Liu L, Fang S, Lu Y, Wei E, and Zhang W (2010) Involvement of cysteinyl leukotriene receptors in angiogenesis in rat thoracic aortic rings. Pharmazie 65:750-754.
31. Yan D, Stocco R, Sawyer N, Nesheim ME, Abramovitz M, and Funk CD (2011) Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT2) agonist, N-methyl-leukotriene C4, in calcium reporter and βarrestin assays. Mol Pharmacol 79:270-278.
32. Yellon DM and Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121-1135.
33. Yuan YM, Fang SH, Qian XD, Liu LY, Xu LH, Shi WZ, Zhang LH, Lu YB, Zhang WP, and Wei EQ (2009) Leukotriene D4 stimulates the migration but not proliferation of endothelial cells mediated by the cysteinyl leukotriene cyslt(1) receptor via the extracellular signal-regulated kinase pathway. J Pharmacol Sci 109:285-292.
34. Zarini S, Gijón MA, Ransome AE, Murphy RC, and Sala A (2009) Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation. Proc Natl Acad Sci U S A 106:8296-8301.
35. Zweier JL (1988) Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury. J Biol Chem 263:1353-1357.